Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up
to 50 sites in North America, Europe and Australia. This study is designed to assess
objective response (OR) [complete response (CR) or partial response (PR)] in subjects with
cutaneous manifestations of CTCL with a requirement for maintenance of such objective
response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally,
this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB,
III, or IVA treated with oral forodesine.